Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor [EPC]

52421 reported adverse events

Drugs of this class: LEDIPASVIR AND SOFOSBUVIR VELPATASVIR AND SOFOSBUVIR SOFOSBUVIR SOFOSBUVIR, VELPATASVIR, AND VOXILAPREVIR

These side effects are most commonly reported by patients taking drugs of the Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor [EPC] class:

# Side effect Count
0 FATIGUE 9265
1 HEADACHE 7702
2 NAUSEA 3918
3 DRUG INEFFECTIVE 3638
4 HEPATITIS C 3050
5 INSOMNIA 2443
6 DIARRHOEA 2407
7 TREATMENT FAILURE 1616
8 ANAEMIA 1583
9 OFF LABEL USE 1581
See all common reactions for Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor [EPC]

Drugs of the Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 HEPATITIS C RNA POSITIVE 78 0.4561
1 GENOTYPE DRUG RESISTANCE TEST POSITIVE 404 0.3930
2 HEPATIC HYDROTHORAX 28 0.3544
3 HEPATITIS C VIRUS TEST POSITIVE 201 0.3418
4 HEPATITIS C RNA 15 0.3261
5 HEPATIC CANCER RECURRENT 88 0.3099
6 HEPATITIS C 3050 0.2524
7 HEPATITIS C RNA INCREASED 68 0.1988
8 AMAUROSIS FUGAX 212 0.1968
9 HEPATOCELLULAR CARCINOMA 1436 0.1886
See all enriched reactions for Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor [EPC]